AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
138.06
+2.27 (1.67%)
Jan 22, 2025, 3:00 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
51.21B
Revenue Growth
+13.81%
P/S Ratio
n/a
Revenue / Employee
569.59K
Employees
89,900
Market Cap
211.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
AstraZeneca News
- 2 days ago - Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN - Accesswire
- 2 days ago - 5 Ideal Buys From 14 'Safer' January Dividends On Bloomberg 2025 Watch List Of 50 - Seeking Alpha
- 2 days ago - FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Benzinga
- 2 days ago - FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Benzinga
- 2 days ago - The Gross Law Firm Notifies Shareholders of AstraZeneca PLC (AZN) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewsWire
- 2 days ago - AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PRNewsWire
- 2 days ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against AstraZeneca PLC - Accesswire
- 2 days ago - Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact Levi & Korsinsky - Accesswire